Cardiometabolic risks during anabolic hormone supplementation in older men.

ABSTRACT:

Objective

To determine the cardiometabolic risks of testosterone and growth hormone (GH) replacement therapy to youthful levels during aging.

Design and methods

A double-masked, partially placebo controlled study in 112 men 65-90 years-old was conducted. Transdermal testosterone (5 g vs. 10 g/day) using a Leydig Cell Clamp and subcutaneous recombinant GH (rhGH) (0 vs. 3 vs. 5 μg/kg/day) were administered for 16-weeks. Measurements included testosterone and IGF-1 levels, body composition by DEXA, and cardiometabolic risk factors (upper body fat, blood pressure, insulin sensitivity, fasting triglycerides, HDL-cholesterol, and serum adiponectin) at baseline and after 16 weeks of treatment.

Results

Some cardiometabolic factors improved (total and trunk fat, triglycerides,

SUBMITTER: He J 

PROVIDER: S-EPMC3930448 | biostudies-literature | 2013 May

REPOSITORIES: biostudies-literature